An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals Limited has announced a webinar to update stakeholders on the recent placement and the commercial launch of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis. The webinar, hosted by key company executives, aims to provide insights into the company’s strategic initiatives and market positioning, potentially impacting its operations and stakeholder interests.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in the development of treatments for skin conditions. The company has received FDA approval for its lead product, Sofdra, which is the first new chemical entity approved for the treatment of primary axillary hyperhidrosis, offering a novel solution for patients with limited treatment options.
YTD Price Performance: -19.32%
Average Trading Volume: 9,594,637
Technical Sentiment Signal: Hold
Current Market Cap: A$650.6M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.